cas 13999-39-8|| where to buy 3-Amino-4,5-dimethylisoxazole

製品名:3-Amino-4,5-dimethylisoxazole

IUPAC Name:dimethyl-1,2-oxazol-3-amine

包装単位	有効在庫	価格（USD）
CM118957-1g	in stock	řǭ
CM118957-5g	in stock	ǭǎǭ
CM118957-25g	in stock	ĜƩǟƏ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 13999-39-8 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:13999-39-8; 分子式:C5H8N2O; 融点:-; SMILESコード:CC1=C(C)C(N)=NO1; 密度:

: カタログ番号:CM118957; 分子量:112.13; 沸点:; MDL番号:MFCD03411577; 保管方法:

: Isoxazoles; Isoxazole is a liquid heterocyclic compound C3H3NO isomeric with oxazole and having a penetrating odor like that of pyridine. Isoxazoles belong to an important class of five-membered aromatic heterocycles containing two electronegative heteroatoms, nitrogen and oxygen, in a 1,2-relationship and three regular sp2 carbon atoms. These molecules are found to be key components in various synthetic products in daily use and also present as a pharmacophore essential for biological activity in many drugs and bioactive natural products. In addition, isoxazoles have demonstrated their ability to exhibit hydrogen bond donor/acceptor interactions with a variety of enzymes and receptors.

: Oxazoles; Oxazoles are heterocyclic aromatic compounds containing one oxygen atom and one nitrogen atom, separated by a carbon atom. The presence of two heteroatoms (oxygen and nitrogen) provides possible interactions (hydrogen, hydrophobic, van der Waals or dipole bonds) with a wide range of receptors and enzymes. Oxazole rings are valuable heterocyclic scaffolds for the design of novel therapeutics with anticancer, antiviral, antibacterial, anti-inflammatory, neuroprotective, antidiabetic, and antidepressant properties due to their wide range of targets and biological activities.

: Sparsentan; CSL Vifor and Travere Therapeutics announce European Commission approves FILSPARI(sparsentan) for the treatment of IgA Nephropathy (IgAN). First non-immunosuppressive therapy for the treatment of IgAN approved in Europe.
Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist with high selectivity for the endothelin A receptor (ETAR) and the angiotensin II subtype 1 receptor (AT1R). Pre-clinical data have shown that blockade of both endothelin type A and angiotensin II type 1 pathways in forms of rare chronic kidney disease, protects podocytes, prevents glomerulosclerosis and mesangial cell proliferation, and reduces proteinuria.